Multiple Sclerosis Drug - Bolder BioTechnology - NIH Grant

Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug

Bolder BioTechnology, Inc. announced today that it has been awarded a $1.6 million Phase II Continuing Renewal Small Business Innovation Research (SBIR) grant, entitled "Long-Acting Beta Interferon for Multiple Sclerosis", from the National Institute of Neurological Disorders and Stroke (NINDS) of The National Institutes of Health (NIH). Receipt of the entire grant award is contingent upon the achievement of certain research milestones.

Biotech News

The new grant award will be used to perform preclinical studies required by the Food and Drug Administration for filing an Investigational New Drug application to begin testing our long-acting beta interferon analog in people. Recombinant beta interferon products have annual worldwide sales of approximately $5 billion, primarily from use of the drugs to treat Multiple Sclerosis. Multiple Sclerosis is a debilitating neurological disease that affects approximately 400,000 people in the United States and 2.5 million people worldwide. Current commercial beta interferon products are only partially effective and are inconvenient to use because they must be injected frequently, typically for the life of the patient. Our long-acting beta interferon analog was designed to provide patients with a more efficacious and easier to use product."

Biotechnology Marketing Biotech Marketing Firm